{"aid": "40218172", "title": "Genetic Markers That Increase Your Risk of Developing MS After Vaccine", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050425/", "domain": "nih.gov", "votes": 1, "user": "hammock", "posted_at": "2024-05-01 00:32:21", "comments": 0, "source_title": "Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?", "source_text": "Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA\nHaplotype Be Determinant? - PMC\n\nSkip to main content\n\nAn official website of the United States government\n\nThe .gov means it\u2019s official. Federal government websites often end in .gov or\n.mil. Before sharing sensitive information, make sure you\u2019re on a federal\ngovernment site.\n\nThe site is secure. The https:// ensures that you are connecting to the\nofficial website and that any information you provide is encrypted and\ntransmitted securely.\n\nLog in\n\n#### Account\n\nLogged in as: username\n\n  * Dashboard\n  * Publications\n  * Account settings\n  * Log out\n\nAccess keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation\n\nPreview improvements coming to the PMC website in October 2024. Learn More or\nTry it out now.\n\n  * Advanced Search\n  * User Guide\n\n  * Journal List\n  * Int J Mol Sci\n  * PMC11050425\n\nAs a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice\n\nInt J Mol Sci. 2024 Apr; 25(8): 4556.\n\nPublished online 2024 Apr 22. doi: 10.3390/ijms25084556\n\nPMCID: PMC11050425\n\nPMID: 38674141\n\n# Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA\nHaplotype Be Determinant?\n\nAssunta Bianco,^1,^2,^*^\u2020 Gabriele Di Sante,^3,^*^\u2020 Francesca Col\u00f2,^2 Valeria\nDe Arcangelis,^1 Alessandra Cicia,^2 Paola Del Giacomo,^4 Maria De Bonis,^5,^6\nTommaso Giuseppe Morganti,^2 Vincenzo Carlomagno,^2 Matteo Lucchini,^1,^2\nAngelo Minucci,^5,^6 Paolo Calabresi,^1,^2 and Massimiliano Mirabella^1,^2\n\n### Assunta Bianco\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Assunta Bianco\n\n### Gabriele Di Sante\n\n^3Department of Medicine and Surgery, Section of Human, Clinical and Forensic\nAnatomy, University of Perugia, 06123 Perugia, Italy\n\nFind articles by Gabriele Di Sante\n\n### Francesca Col\u00f2\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Francesca Col\u00f2\n\n### Valeria De Arcangelis\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\nFind articles by Valeria De Arcangelis\n\n### Alessandra Cicia\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Alessandra Cicia\n\n### Paola Del Giacomo\n\n^4Department of Laboratory and Infectious Sciences, Fondazione Policlinico\nUniversitario A. Gemelli IRCCS, 00168 Rome, Italy\n\nFind articles by Paola Del Giacomo\n\n### Maria De Bonis\n\n^5Departmental Unit of Molecular and Genomic Diagnostics, Fondazione\nPoliclinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\n^6Genomics Core Facility, Gemelli Science and Technology Park (G-STeP),\nFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\nFind articles by Maria De Bonis\n\n### Tommaso Giuseppe Morganti\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Tommaso Giuseppe Morganti\n\n### Vincenzo Carlomagno\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Vincenzo Carlomagno\n\n### Matteo Lucchini\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Matteo Lucchini\n\n### Angelo Minucci\n\n^5Departmental Unit of Molecular and Genomic Diagnostics, Fondazione\nPoliclinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\n^6Genomics Core Facility, Gemelli Science and Technology Park (G-STeP),\nFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\nFind articles by Angelo Minucci\n\n### Paolo Calabresi\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Paolo Calabresi\n\n### Massimiliano Mirabella\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\nFind articles by Massimiliano Mirabella\n\nSang Won Suh, Academic Editor\n\nAuthor information Article notes Copyright and License information PMC\nDisclaimer\n\n^1Division of Neurology, Fondazione Policlinico Universitario A. Gemelli\nIRCCS, 00168 Rome, Italy\n\n^2Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla\n\u201cAnna Paola Batocchi\u201d, Catholic University of Sacred Heart, 00168 Rome, Italy\n\n^3Department of Medicine and Surgery, Section of Human, Clinical and Forensic\nAnatomy, University of Perugia, 06123 Perugia, Italy\n\n^4Department of Laboratory and Infectious Sciences, Fondazione Policlinico\nUniversitario A. Gemelli IRCCS, 00168 Rome, Italy\n\n^5Departmental Unit of Molecular and Genomic Diagnostics, Fondazione\nPoliclinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\n^6Genomics Core Facility, Gemelli Science and Technology Park (G-STeP),\nFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy\n\n^*Correspondence: ti.ttacinu@ocnaib.atnussa (A.B.); ti.gpinu@etnasid.eleirbag\n(G.D.S.)\n\n^\u2020These authors contributed equally to this work.\n\nReceived 2024 Mar 17; Revised 2024 Apr 13; Accepted 2024 Apr 18.\n\nCopyright \u00a9 2024 by the authors.\n\nLicensee MDPI, Basel, Switzerland. This article is an open access article\ndistributed under the terms and conditions of the Creative Commons Attribution\n(CC BY) license (https://creativecommons.org/licenses/by/4.0/).\n\n## Associated Data\n\nSupplementary Materials\n\n    \n\nijms-25-04556-s001.zip (104K)\n\nGUID: FA8772AE-663C-420D-917E-16B317C33237\n\nData Availability Statement\n\n    \n\nThe datasets analysed during the current study are available from the\ncorresponding author upon reasonable request.\n\nGo to:\n\n## Abstract\n\nA few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have\nbeen reported, although the evidence is insufficient to establish causality.\nThe aim of this study is to compare cases of newly diagnosed\nrelapsing\u2013remitting MS before and after the outbreak of the COVID-19 pandemic\nand the impact of COVID-19 vaccination. Potential environmental and genetic\npredisposing factors were also investigated, as well as clinical patterns.\nThis is a single-centre retrospective cohort study including all patients who\npresented with relapsing\u2013remitting MS onset between January 2018 and July\n2022. Data on COVID-19 vaccination administration, dose, and type were\ncollected. HLA-DRB1 genotyping was performed in three subgroups. A total of\n266 patients received a new diagnosis of relapsing\u2013remitting MS in our centre,\n143 before the COVID-19 pandemic (until and including March 2020), and 123\nduring the COVID-19 era (from April 2020). The mean number of new MS onset\ncases per year was not different before and during the COVID-19 era and\nneither were baseline patients\u2019 characteristics, type of onset, clinical\nrecovery, or radiological patterns. Fourteen (11.4%) patients who subsequently\nreceived a new diagnosis of MS had a history of COVID-19 vaccination within\none month before symptoms onset. Patients\u2019 characteristics, type of onset,\nclinical recovery, and radiological patterns did not differ from those of\npatients with non-vaccine-related new diagnoses of MS. The allele frequencies\nof HLA-DRB1*15 were 17.6% and 22.2% in patients with non-vaccine-related\ndisease onset before and during the COVID-19 era, respectively, while no case\nof HLA-DRB1*15 was identified among patients with a new diagnosis of MS post-\nCOVID-19 vaccine. In contrast, HLA-DRB1*08+ or HLA-DRB1*10+ MS patients were\npresent only in this subgroup. Although a causal link between COVID-19\nvaccination and relapsing\u2013remitting MS cannot be detected, it is interesting\nto note and speculate about the peculiarities and heterogeneities underlying\ndisease mechanisms of MS, where the interactions of genetics and the\nenvironment could be crucial also for the follow-up and the evaluation of\ntherapeutic options.\n\nKeywords: multiple sclerosis, SARS-CoV-2 vaccination, COVID-19 and autoimmune\ndisorders, HLA-DRB1 risk factors\n\nGo to:\n\n## 1\\. Introduction\n\nMultiple sclerosis (MS) is a chronic, immune-mediated disease of the central\nnervous system (CNS) characterized by focal demyelination and\nneurodegeneration. The aetiopathogenesis of MS is multifactorial, and\nenvironmental factors have been shown to have a considerable impact on\nsusceptible individuals [1,2,3]. Among triggers, viral infections have been\nassociated with an increased risk of developing MS [4,5,6,7,8], and a direct,\ncausal relation has recently been established for the Epstein\u2013Barr virus (EBV)\n[9]. Active immunization with vaccines has been also hypothesized as a\npossible trigger for MS onset on the assumption that immune stimulation may\nlead to a dysregulated, auto-aggressive response. Nevertheless, the risk of\ndeveloping MS after vaccinations against Hepatitis B virus, Human\nPapillomavirus, seasonal influenza and H1N1, measles\u2013mumps\u2013rubella, Variola,\ntetanus, Bacillus Calmette\u2013Gu\u00e9rin, Poliovirus, typhoid fever, and diphtheria\nhas not been proven [10,11,12].\n\nThe recent COVID-19 pandemic and the subsequent vaccination campaign have\nraised a new debate on the mutual relations between viral infections,\nvaccinations, and MS. The massive inflammatory response induced by SARS-CoV-2\ninfection is peculiar compared to other viruses [13,14] and has been\nassociated with the occurrence of many para- and post-infectious inflammatory\nneurological conditions, like acute disseminated encephalomyelitis (ADEM)\n[15,16] and neuromyelitis optica spectrum disorders (NMOSDs) [17,18]. A few\ncases of typical onset of MS during or post-COVID-19 have been reported as\nwell, although the evidence is insufficient to establish a causative role of\nthe SARS-CoV-2 virus [19,20,21,22,23].\n\nAfter the early stages of vaccination campaigns, in late 2020, many cases of\nneurological disorder onset after vaccination were reported [24,25,26,27]. A\nfew cases of reactivation or new onset of demyelinating diseases of the CNS\nhave been described as well, both after vaccination with mRNA-based\n[28,29,30,31] and with adenovirus-vectored formulations of the vaccine\n[31,32,33]. The assumption that anti-COVID-19 vaccination may increase the\nrisk of developing MS is still debated, and this potential causal relationship\ncould change the risk\u2013benefit profile of anti-COVID-19 vaccination, at least\nin some population subgroups. Genetic and environmental predisposing factors\nfor the onset of demyelinating disease after the vaccine in predisposed\nindividuals have not yet been defined.\n\nThe T-cell-mediated self-reactivity against myelin is strongly linked to the\nhuman leucocyte antigen (HLA)-DRB1. In particular, the HLA-DRB1*15 haplotype\nrepresents the single genetic factor with the strongest association with\nrelapsing\u2013remitting MS [34,35,36], although more recent genome-wide\nassociation studies showed extreme complexity of interactions between genes\nand immune response in the development of MS [37,38].\n\nThis study aimed to compare cases of newly diagnosed relapsing\u2013remitting MS\nreported to our MS centre before and after the outbreak of the COVID-19\npandemic and their temporal relationship with SARS-CoV-2 vaccination.\nPotential environmental and genetic predisposing factors were also\ninvestigated, as well as clinical patterns of the post-vaccine MS cohort and a\ntypical newly diagnosed MS cohort.\n\nGo to:\n\n## 2\\. Results\n\n### 2.1. Comparison between Patients with a Disease before and during the\nCOVID-19 Pandemic\n\nDuring the study period (January 2018\u2013July 2022), 266 patients received a new\ndiagnosis of relapsing\u2013remitting MS at our centre, 143 before the SARS-CoV-2\noutbreak (until and including March 2020), and 123 during the COVID-19 era\n(from April 2020). The mean number of new MS onset was 64 per year before the\nCOVID-19 era and 56 per year during the COVID-19 era; a statistically\nsignificant difference was not detectable (Figure 1). Similarly, the number of\nnew MS onset per trimester was not statistically different before and during\nthe COVID-19 era (Figure 2). One hundred eighty-five (69.5%) patients were\nfemale, with a median age of 34 years, and 10.8% of them had another\nassociated autoimmune disease. The most common onset types were spinal\n(27.1%), multisystemic (21.4%), and brain stem (19.9%). Oligoclonal bands were\npositive in 83.5% of patients. Median EDSS after relapse was 1.0. Complete or\npartial recovery after pulse steroid treatment was observed in 93.6% of\npatients. MRI at onset showed a median of five supratentorial T2 lesions;\n54.1% of patients showed at least one gadolinium-enhancing lesion. A\ncomparison between patients with a new diagnosis of MS before and during the\nCOVID-19 era showed no difference in patients\u2019 characteristics, type of onset,\nclinical recovery, and radiological patterns; during the COVID-19 era, the\ntime from onset to diagnosis was lower than that of patients diagnosed before\nSARS-CoV-2 advent (Table 1). None of the patients of the MS cohort with\ndisease onset during the COVID-19 pandemic documented or experienced a SARS-\nCoV-2 infection within 1 month before symptoms onset.\n\nOpen in a separate window\n\nFigure 1\n\nMean number of new MS onset cases per year; Pre-COVID-19 era: January\n2018\u2013March 2020; and Post-COVID-19 era: April 2020\u2013July 2022. A statistically\nsignificant difference was not found.\n\nOpen in a separate window\n\nFigure 2\n\nNumber of new SM onset cases per trimester, January 2018 to July 2022; the\nKruskal\u2013Wallis test was applied, and no significant differences between groups\nhave been found.\n\n### Table 1\n\nComparison between patients with a new diagnosis of MS in the pre-COVID-19 era\nand during the COVID-19 era.\n\nBefore COVID-19 Era| During COVID-19 Era| p-Value  \n---|---|---  \nPatients with a new diagnosis of MS| 143| 123  \nWomen (%)| 105/143 (73.4%)| 80/123 (65.0%)| 0.178  \nAge in years\u2014median (IQR)| 33.0 (25.82\u201339.89)| 33.0 (25.82\u201339.89)| 0.052  \nFamily history of MS (%)| 8/143 (5.6%)| 10/123 (8.1%)| 0.565  \nAutoimmune comorbidity (%)| 18/143 (12.6%)| 7/123 (5.7%)| 0.087  \nTime from onset to diagnosis\u2014median (IQR)| 7.0 (1.97\u20137.70)| 4.0 (1.97\u20137.70)|\n<0.001  \nType of onset| 0.081  \nOptic neuritis (%)| 29/143 (20.3%)| 21/123 (17.1%)  \nBrain stem (%)| 31/143 (21.6%)| 22/123 (17.9%)  \nCerebellum (%)| 3/143 (2.1%)| 1/123 (0.8%)  \nSpinal cord (%)| 38/143 (26.6%)| 34/123 (27.6%)  \nSupratentorial (%)| 20/143 (14.0%)| 10/123 (8.1%)  \nMultisystemic (%)| 22/143 (15.4%)| 35/123 (28.5%)  \nOligoclonal bands (%)| 122/139 (87.8%)| 100/110 (90.9%)| 0.528  \nEDSS at onset\u2014median (IQR)| 2.0 (1.50\u20132.5)| 2.0 (1.50\u20132.5)| 0.097  \nEDSS after relapse\u2014median (IQR)| 1.0 (1.50\u20132.5)| 1.0 (1.50\u20132.5)| 0.905  \nClinical recovery after pulsed steroid therapy| 0.372  \nNone (%)| 7/143 (4.9%)| 10/123 (8.1%)  \nPartial (%)| 89/143 (62.2%)| 74/123 (60.2%)  \nFull (%)| 48/143 (33.6%)| 38/123 (30.9%)  \nMRI brain stem (%)| 60/143 (42.0%)| 49/123 (39.8%)| 0.822  \nMRI cerebellum| 41/143 (28.7%)| 35/123 (28.5%)| 1.000  \nMRI spinal cord (%)| 99/143 (69.2%)| 93/123 (75.6%)| 0.308  \nMRI infratentorial (%)| 79/143 (55.2%)| 61/123 (49.6%)| 0.506  \nMRI number of supratentorial lesions\u2014median (IQR)| 5 (3.0\u20139.0)| 5 (3.0\u20139.0)|\n0.215  \nMRI contrast enhancement (%)| 76/143 (53.1%)| 68/123 (55.3%)| 0.637  \nHighly active efficacy therapy (%)| 62/143 (43.4%)| 60/114 (52.6%)| 0.218  \nSmoke (%)| 46/143 (32.2%)| 41/123 (33.3%)| 0.943  \nVitamin D\u2014median (IQR)| 23.9 (17.55\u201330.76)| 23.9 (17.55\u201330.76)| 0.564  \nBMI (kg/m^2)\u2014median (IQR)| 23.6 (21.30\u201326.23)| 23.6 (21.30\u201326.23)| 0.383  \nEBV positive serology (%)| 124/143 (86.7%)| 110/123 (89.4%)| 0.065  \n  \nOpen in a separate window\n\n### 2.2. Analysis of MS Cohort with a SARS-CoV-2 Vaccine-Related Disease Onset\n\nFourteen (11.4%) patients who subsequently received a new diagnosis of MS had\na history of SARS-CoV-2 vaccination within one month before symptom onset. The\ndemyelinating event occurred after the first dose vaccination in three\npatients, after the second dose vaccination in seven patients, and after\nbooster dose vaccination in four patients (Figure 3). Ten patients received\nm-RNA BNT162b2 (Figure 3), three patients received mRNA-1273, and one patient\nreceived heterologous vaccination (ChAdOx1-S/mRNA-1273). Patients\u2019\ncharacteristics, type of onset, clinical recovery, and radiological patterns\ndid not differ from those of patients with non-vaccine-related new diagnoses\nof MS (Table 2). A sub-analysis was performed to test the hypothesis of\nwhether patients with post-vaccine onset differed in the severity of disease.\nNo statistically significant difference was detectable in the EDSS in\npresentation, type of relapse, and recovery after relapse in univariate\nanalysis post-PSM (Supplementary Table S1).\n\nOpen in a separate window\n\nFigure 3\n\nIn the first diagram, the distribution of vaccines in our cohort (266\npatients) is represented; in the second diagram, we represent the types of\ndoses administered to patients who, after that, presented a post-vaccine MS\nonset.\n\n### Table 2\n\nComparison between patients with post-vaccine and non-vaccine-related new\ndiagnosis of MS considering a maximum of 1 month between SARS-CoV-2\nvaccination and demyelinating event onset.\n\nPost-Vaccine New Diagnosis of MS| Non-Vaccine-Related New Diagnosis of MS|\np-Value  \n---|---|---  \nNumber of patients with a new diagnosis of MS| 14| 252  \nWomen (%)| 11/14 (78.6%)| 174/252 (69.0%)| 0.623  \nAge in years\u2014median (IQR)| 33.0 (26.00\u201340.00)| 33.0 (26.00\u201340.00)| 0.321  \nFamily history of MS (%)| 1/14 (7.1%)| 16/252 (6.3%)| 1.000  \nAutoimmune comorbidity (%)| 0/14 (0.0%)| 24/252 (9.5%)| 0.456  \nTime from onset to diagnosis\u2014median (IQR)| 4.0 (1.97\u20137.70)| 4.0 (2.00\u20138.00)|\n0.869  \nType of onset| 0.379  \nOptic neuritis (%)| 0/14 (0.0%)| 50/252 (19.8%)  \nBrain stem (%)| 5/14 (35.7%)| 48/252 (19.0%)  \nCerebellum (%)| 0/14 (0.0%)| 4/252 (1.6%)  \nSpinal cord (%)| 4/14 (28.6%)| 68/252 (27.0%)  \nSupratentorial (%)| 1/14 (7.1%)| 29/252 (11.5%)  \nMultisystemic (%)| 4/14 (28.6%)| 53/252 (21.0%)  \nOligoclonal bands (%)| 10/12 (83.3%)| 212/237 (89.5%)| 0.863  \nEDSS at onset\u2014median (IQR)| 2.0 (1.50\u20132.50)| 2.0 (1.50\u20132.50)| 0.328  \nEDSS after relapse\u2014median (IQR)| 1.0 (0.00\u20131.50)| 1.0 (0.00\u20131.50)| 0.264  \nClinical recovery after pulsed steroid therapy| 0.180  \nNone (%)| 1/14 (7.1%)| 14/252 (5.6%)  \nPartial (%)| 3/14 (21.4%)| 151/252 (59.9%)  \nFull (%)| 4/14 (28.6%)| 82/252 (32.5%)  \nMRI brain stem (%)| 6/14 (42.9%)| 103/252 (40.9%)| 1.000  \nMRI cerebellum (%)| 5/14 (35.7%)| 71/252 (28.2%)| 0.688  \nMRI spinal cord (%)| 10/14 (71.4%)| 182/252 (72.2%)| 1.000  \nMRI infratentorial (%)| 9/14 (64.3%)| 132/252 (52.4%)| 0.517  \nMRI number of supratentorial lesions\u2014median (IQR)| 5.0 (3.00\u20139.00)| 5.0\n(3.00\u20139.00)| 0.428  \nMRI contrast enhancement (%)| 11/14 (78.6%)| 131/252 (52.0%)| 0.102  \nHighly active efficacy therapy (%)| 8/10 (80.0%)| 114/246 (46.3%)| 0.073  \nSmoke (%)| 4/14 (28.6%)| 83/252 (32.9%)| 0.931  \nVitamin D\u2014median (IQR)| 23.9 (17.55\u201330.76)| 23.9 (17.55\u201330.76)| 0.431  \nBMI (kg/m^2)\u2014median (IQR)| 23.6 (21.30\u201326.23)| 23.6 (21.30\u201326.23)| 0.334  \nEBV positive serology (%)| 13/14 (92.9%)| 205/252 (81.3%)| 0.544  \n  \nOpen in a separate window\n\nAn additional four patients developed inflammatory demyelinating events within\nthe second month after vaccine exposure (three patients after the second dose\nand one patient after the booster dose); three patients received heterologous\nvaccination (ChAdOx1-S/mRNA BNT162b2), and one patient received BNT162b2.\nPatients\u2019 characteristics, type of onset, clinical recovery, and radiological\npatterns are shown in Supplementary Table S2 and did not differ from patients\nwith non-vaccine-related new diagnoses of MS.\n\n### 2.3. Comparison of HLA-DRB1 Genotyping before and during COVID-19 Pandemic\n\nHLA genotyping was performed on plasma samples collected from 49 MS patients:\n17 patients with disease onset before the COVID-19 era (control group 1), 18\npatients with disease onset during the COVID-19 era but not vaccine-related\n(control group 2), and all 14 patients with a post-vaccine new diagnosis of MS\n(cases). HLA-DRB1 alleles in the three groups are reported in Table 3 and\nSupplementary Table S3. The allele frequencies of HLA-DRB1*15 were 17.6% and\n22.2% in control groups 1 and 2, respectively, but none of the patients with a\nnew diagnosis of MS post-COVID-19 vaccine resulted in HLA-DRB1*15 at least in\none of the two alleles, while HLA-DRB1*08^pos and HLA-DRB1*10^pos MS patients\nwere present only in the subgroup of our cohort with a vaccine-related disease\nonset (Figure 4).\n\nOpen in a separate window\n\nFigure 4\n\nHLA-DRB1 haplotypes. Comparison of HLA-DRB1 haplotypes (both alleles) among 17\npatients with disease onset in the pre-COVID-19 era (control group 1), 18\npatients with disease onset in the post-COVID-19 era but not vaccine-related\n(control group 2), and 14 patients with a post-vaccine new diagnosis of MS\n(cases). Each line indicates a single patient. Positive HLA-DRB1 alleles with\na square filled in light blue for heterozygous and dark blue for homozygous.\nIn the red box, the column concerning HLA-DRB1*15 is not expressed in the\nsubgroups of MS patients with disease onset related to vaccination.\n\n### Table 3\n\nComparison among 17 patients with disease onset in the pre-COVID-19 era\n(control group 1), 18 patients with disease onset in the post-COVID-19 era but\nnot vaccine-related (control group 2), and all 14 patients with a post-vaccine\nnew diagnosis of MS (cases). Most relevant HLA-DRB1 alleles are displayed as\nallele frequencies. Sums of positives were not intended as a total due to the\npresence for each MS patient of two alleles that in a few cases are present in\nhomozygosis.\n\nHLA-DRB1 Alleles of Patients with a New Diagnosis of MS.  \n---  \nHLA-DRB1 Alleles| Pre-COVID-19 Era| COVID-19 Era  \nVaccine-Unrelated Onset| Vaccine-Related Onset  \nHLA-DRB1*01, n (%)| 2.0 (11.8)| 4.0 (22.2)| 2.0 (14.3)  \nHLA-DRB1*03, n (%)| 5.0 (29.4)| 6.0 (33.3)| 3.0 (21.4)  \nHLA-DRB1*04, n (%)| 3.0 (17.6)| 2.0 (11.1)| 2.0 (14.3)  \nHLA-DRB1*07, n (%)| 5.0 (29.4)| 4.0 (22.2)| 2.0 (14.3)  \nHLA-DRB1*11, n (%)| 5.0 (29.4)| 3.0 (16.7)| 2.0 (14.3)  \nHLA-DRB1*13, n (%)| 4.0 (23.5)| 3.0 (16.7)| 5 (35.7)  \nHLA-DRB1*15, n (%)| 3.0 (17.6)| 4.0 (22.2)| 0  \n  \nOpen in a separate window\n\nGo to:\n\n## 3\\. Discussion\n\nOur study showed a different HLA genotype pattern in patients with\nrelapsing\u2013remitting MS onset within one month after the COVID-19 vaccine\ncompared to both patients with non-vaccine-related MS onset and patients with\nMS onset before the COVID-19 pandemic. The genotype of HLA is not modifiable\nby immune response in any case, but, interestingly, we observed that certain\nHLA haplotypes recurred more frequently in patients with MS onset within one\nmonth after the COVID-19 vaccine. In this case, the genotype is a\nprerequisite, and probably the immune system after the vaccine in selected\npeople with a genetic predisposition and probably with certain HLA haplotypes\ncan enhance specific mechanisms of response, in some cases protective and\nothers dangerous. Self-reactive mechanisms are largely involved in MS\npathogenesis, where CNS-reactive T and B cells play a prominent role\n[39,40,41,42]. Thus, peripherally activated T cells specific for myelin\nantigens become able to cross the blood\u2013brain barrier [43,44]. After reaching\nCNS, they recognize specific targets able to re-stimulate them through local\nantigen-presenting cells (APCs) [45,46,47], causing damage to myelin sheaths\nand recruitment of other immune cells [48,49,50,51], leading to demyelination.\nThe T cell-mediated self-reactivity against myelin is strongly linked to the\nhuman leucocyte antigen HLA-DRB1*15 allele (HLA-DR2) [52]. Although it is well\nknown that the HLA-DRB1*15 haplotype represents a single genetic factor with\nthe strongest association with MS [36], especially with relapsing\u2013remitting MS\n(OR = 3.08), more recent genome-wide association studies (GWASs) dissected the\nvarious and heterogeneous universe of genes associated with MS [37,38], while\ncell-specific fine-mapping revealed the complexity of these interactions,\nproviding novel evidence about the potential genetic mechanisms that\nindependently involve T and B cells in the pathogenesis of MS [53]. These\nfindings are embedded in the long-standing debate regarding the aetiology of\nMS, corroborating the causal role of both CD4 T cells, including Th17 T cells,\nand memory B cells [3,54,55], confirmed by the highly effective therapies\ntargeting these subpopulations [56].\n\nIn this study, we intended to compare relapsing\u2013remitting MS cohorts based on\ntheir onset in three distinct periods: before and during the COVID-19 era,\ndistinguishing between MS patients with demyelinating event onset within 1\nmonth after COVID-19 vaccination and patients with non-vaccine-related MS\nonset. The time interval by which to define a temporal relationship between a\ntriggering event (e.g., a vaccine) and the onset of MS is controversial. We\nestablished a one-month timeframe based on recent literature about\ninflammatory events related to SARS-CoV-2 vaccination [26]; the same timeframe\nwas chosen by Alluqmani in his case\u2013control study including thirty-two\npatients with vaccine-related MS onset [31].\n\nThe association between COVID-19 vaccination and MS onset is still debated in\nthe literature [57,58]. Havla and Coll. described a case of MS onset in a\n28-year-old woman six days after the first dose of the BNT162b2 mRNA vaccine\n[28]. Khayat-Khoei and Coll. described three cases of new-onset MS or\nneuromyelitis optica and four cases of exacerbation of known stable MS within\n21 days after the first or second dose of the mRNA-1273 or the BNT162b2\nvaccines [29]. Toljan and Coll. described a series of five patients who\ndeveloped MS during 1-day and two-month timeframes after an mRNA-based\nCOVID-19 vaccine [31]. In the Oxford COVID Vaccine Trial, one case of MS\nreactivation 10 days after the first dose of the ChAdOx1 vaccine was observed\namong 11,636 participants [32]. Rinaldi and Coll. collected three cases of MS\nonset occurring within 35 days after the COVID-19 vaccine and performed a\nsystematic review that included 47 cases of MS onset/reactivation after the\nCOVID-19 vaccine [33]. To avoid confounding, we evaluated only demyelinating\nevents at disease onset in our study, not including cases of MS reactivation\nas reported in other works [33,59,60]. In our study, we were not able to find\nany demographic, clinical, or radiological differences between patients with\npost-vaccine new-onset MS and patients with non-vaccine-relate MS onset.\nEstablishing a causal relationship between vaccination against COVID-19 and\nthe onset of MS is outside the objectives of this study, although the mean\nnumber of new MS onset cases per year was not different before and during the\nCOVID-19 era in our centre. To confirm or deny a causal association between\nvaccination against COVID-19 and MS onset, one or more case\u2013control studies in\nlarge populations will be needed, as was the case for vaccinations against HBV\nand HPV [10].\n\nThe HLA-DRB1 genotyping of MS patients reflects frequencies normally expected\nboth in line with the Italian reference population (allefrequencies.net, last\nvisit to website: 6 June 2023) [61] and with what is generally expected in MS\npatient cohorts [34,35]. There is a slight non-significant prevalence of\ncertain alleles generally associated with autoimmune diseases, and the\nhaplotype combinations reflect those most frequent in the reference\npopulation. Intriguingly, the genotyping of HLA-DRB1, comparing the patients\nbased on disease onset (before or during the COVID-19 pandemic and related or\nunrelated to SARS-CoV-2 vaccination), revealed that none of the MS patients\nwith demyelinating event onset within one month after COVID-19 vaccination\nexpressed the HLA-DRB1*15 allele. In contrast, the HLA-DRB1*08 and HLA-DRB1*10\nalleles were expressed in the vaccine-related onset cohort but not in the\nother two groups of MS patients with disease onset unrelated to either SARS-\nCoV-2 infection or vaccination.\n\nAlthough these observations regard a small number of individuals, these\nresults are intriguing and open to distinct speculations. First, the HLA-\nDRB1*15 allele generally averages around one-fifth of MS Caucasian Italian\npatients [34,35,56]. The fact that no patient in this group presented the\nsingle genetic risk factor related to MS and was able to evoke a mechanism\nmediated by abnormal antigen presentation and autoimmune T lymphocyte\nrecruitment processes may suggest that other potential mechanisms are\npredominant, probably triggered by the vaccination itself or other bystander\neffects following the vaccination. This paper does not intend to find a causal\nlink between COVID-19 vaccination and MS, in line with the literature where\nthis topic remains still controversial [28,29,30,31,59,60]. Heterogeneous\nhumoral and cellular immune responses to the different doses and formulations\nof COVID-19 vaccination have been widely reported [62,63]. In line with this,\nthe alleles exclusively expressed in the vaccine-related cohort, although\nrarely and poorly associated with immune-related disorders, have been\ndescribed to be predisposing risk factors for MS and other autoimmune diseases\n(HLA-DRB1*08 [64,65]) and IgG4 mediated encephalopathies and neuromyelitis\noptica (HLA-DRB1*10 [66,67,68,69]). The fact that HLA-DRB1*08^pos and HLA-\nDRB1*10^pos MS patients are limited to the cohort of those with a disease\nonset related to SARS-CoV-2 vaccination suggests a possible B cell or\nantibodies-mediated mechanism(s) probably responsible for initiating or\ntriggering the disease in individuals predisposed to or at risk of developing\nMS.\n\nNevertheless, it will be interesting to follow up on the evolution of the\ndisease in these patients and to understand whether they will develop a more\nsevere course over time or be amenable to more targeted therapies. For\nexample, we can speculate that they might benefit from an approach more\ndirected at the B cell compartment, being prevalent T cell-independent\nmechanisms in their pathogenesis.\n\nOur study has several limitations. It was not possible to analyse the HLA\npattern for all patients included in the study. However, we analysed all\npatients with a post-COVID-19 vaccine new diagnosis of MS and an equivalent\nnumber of patients in the two control groups. Our study did not include a\nhealthy individual control group. However, since we enrolled only non-\nSardinian Italian Caucasian patients, we used the data available on the\ngeneral Italian population as a reference for the frequencies of the HLA\nhaplotypes. Furthermore, being a single-centre study, its generalizability\nrequires further confirmation.\n\nA detailed discussion of the efficacy and safety of COVID-19 vaccination in\npatients who already have a diagnosis of MS (whether or not being treated with\ndisease-modifying drugs) is outside the objectives of this study.\n\nGo to:\n\n## 4\\. Materials and Methods\n\n### 4.1. Study Population\n\nThis is a single-centre retrospective cohort study conducted at the MS Centre\nof Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, a\nteaching hospital that oversees about 1500 MS patients. Inclusion criteria\nencompassed all patients who presented with a first neurological event\nsuggestive of relapsing\u2013remitting MS between January 2018 and July 2022 and\nwho were successively diagnosed with MS according to the 2017 revision of\nMcDonald\u2019s criteria [70]. Data were collected from the review of medical\nrecords. For each patient, we evaluated the following characteristics at\ndisease onset: smoking habit; body mass index (BMI); vitamin D levels;\nexposure to EBV; the presence, number, and localization of T2-FLAIR and\ngadolinium-enhancing lesions on magnetic resonance imaging (MRI); and the\nExpanded Disability Status Scale (EDSS) score. We also assessed clinical\nrecovery after the first clinical event and after the first treatment started.\nData on SARS-CoV-2 vaccination included the dates of administration of each\ndose and the type of vaccine (BNT162b2\u2014Comirnaty\u00a9 (BioNTech/Pfizer, Mainz,\nGermany/New York, NY, USA), mRNA-1273\u2014Spikevax\u00a9 (Moderna, Cmbridge MA, USA),\nChAdOx1-S\u2014Vaxzevria\u00a9 (AstraZeneca PLC, Cambridge, UK), and\nAd26.COV2.S\u2014Johnson&Johnson\u00a9, Titusville, NJ, USA). For patients newly\ndiagnosed with MS after 2020, we collected the time from vaccination to\ndisease onset. For patients presenting with MS within 1 month from any dose of\nvaccine, we conducted genetic testing on blood samples, as well as in control\ngroups as described below. Written consent was obtained from all patients.\nAnonymized data not published within this article are available upon request.\n\n### 4.2. SARS-CoV-2 Vaccination\n\nIn Italy, the COVID-19 vaccination campaign started on 27 December 2020. The\nfirst vaccines available were mRNA vaccines and included BNT162b2\u2013Comirnaty\u00a9\n(two intramuscular injections 21 days apart) [71] and mRNA-1273\u2014Spikevax\u00a9 (two\nintramuscular injections 28 days apart) [72]. Non-replicating vector vaccines,\nnamely ChAdOx1-S\u2014Vaxzevria\u00a9 (two intramuscular injections 4\u201312 weeks apart)\n[73] and Ad26.COV2.S\u2014Johnson&Johnson\u00a9 (only one intramuscular injection) [74],\nwere available from February 2021 and April 2021, respectively.\n\nAge and pre-existing medical conditions as the main variables associated with\nmortality from COVID-19 guided the order of priority for vaccination starting\nwith people aged over 80 and people at risk of developing severe COVID-19,\nincluding patients suffering from neurological conditions such as MS [75].\nOther categories were also identified as priority groups, regardless of age\nand pre-existing medical conditions, such as caregivers of frail people,\nsocial and healthcare workers on the frontline of the COVID-19 response,\nschool staff, etc. After that, vaccination was offered to the remaining\npopulation.\n\nIn April 2021, ChAdOx1-S and Ad26.CoV2.S. distribution was restricted to\npeople older than 60 years due to some reports of cases of severe\nthromboembolism in younger people. Since then, the vaccination campaign has\nbeen carried out almost entirely through mRNA-based vaccines (European\nCOVID-19 vaccine-safety-update; website last visited: 31 May 2023) [76].\n\nFrom October 2021, a booster dose with one of the two m-RNA vaccines\n(original/omicron BA.1 or original/omicron BA.4\u20135) was offered to subjects who\ncompleted the primary series in order of priority. Since April 2022, a second\nbooster dose has been gradually recommended to a wider target population once\nat least 120 days have elapsed since the last dose or the last SARS-CoV-2\ninfection.\n\nIn Italy, 145,134,032 vaccine doses have been administered until July 2022\n(Italian Task Force COVID-19 update; website last visited: 13 March 2024)\n[77].\n\n### 4.3. HLA-DR Genotyping\n\nGenomic DNA for HLA-DR genotyping was extracted using QIAamp DNA Mini kits\n(Qiagen GmbH, Hilden, Germany); it was amplified in the region of exon 2 of\nHLA-DRB1 through PCR and then was reversely hybridized using the INNO-LiPA\nHLA-DRB1 plus kit (Fujirebio Italia, Pomezia, Italy), following the\nmanufacturer\u2019s instructions [77,78]. LiRAS software version 2.0 also provided\nby Fujirebio was used for the interpretation of HLA-DRB1 probes on the\nhybridization strips to predict one-digit HLA-DRB1 [79,80].\n\n### 4.4. Statistical Analysis\n\nWe described the general characteristics of the population with summary\nstatistics. We used the Mann\u2013Whitney U-test and Pearson\u2019s chi-square\ntest/Fisher\u2019s exact test as appropriate to test differences between groups. We\nused the Shapiro\u2013Wilk test as the normality test. We evaluated univariate\nassociations between patients diagnosed with MS during the pre-COVID-19 era\nand during the COVID-19 era.\n\nTo define a possible temporal association between SARS-CoV-2 vaccination and\nthe onset of the acute demyelinating event, we established a one-month\ntimeframe based on recent literature about inflammatory events related to\nSARS-CoV-2 vaccination [26]; a two-month timeframe was also investigated\naccording to the classical relationship between demyelinating events and\nvaccination by Confavreux [81].\n\nSince our patients were not randomized, we used propensity score matching\n(PSM) to estimate differences in outcome measures between patients diagnosed\nafter SARS-CoV-2 vaccination and all other patients, considering a maximum of\none month between vaccination and MS onset. Covariates included in this model\nwere age, sex, smoke, positive EBV serology, vitamin D serum levels, and BMI\n(kg/m^2). The \u201cgreedy nearest neighbor\u201d matching method was used to find pairs\nof observations that have very similar propensity scores, setting a caliper of\n0.02. The significance threshold was set at 5%. All analyses were performed\nusing R software v.4.1.3 (https://www.r-project.org, accessed on 10 October\n2023).\n\nGo to:\n\n## 5\\. Conclusions\n\nThese data, although limited by the restricted number of patients, once again\ncorroborate and confirm the idea that the etiopathogenesis of\nrelapsing\u2013remitting MS can be determined by a myriad of factors, of both\ngenetic and environmental origins, whose interactions lead in some individuals\nto the development of the disease and, more generally, of autoimmune disorders\n[82,83,84,85,86]. Understanding these individual factors could have a great\nimpact on managing patients and choosing the best treatment options. Our study\nalso demonstrates the need for in-depth context-specific genetic and\nenvironmental data to carefully delineate the causal role and the potential\nevolution of each MS case individually.\n\nGo to:\n\n## Supplementary Materials\n\nThe following supporting information can be downloaded at:\nhttps://www.mdpi.com/article/10.3390/ijms25084556/s1.\n\nClick here to view.^(104K, zip)\n\nGo to:\n\n## Funding Statement\n\nThis research received no external funding.\n\nGo to:\n\n## Author Contributions\n\nConceptualization, A.B. and G.D.S.; acquisition, analysis, and interpretation\nof the data: V.D.A., A.C., T.G.M. and V.C.; genetic analysis: G.D.S., M.D.B.\nand A.M.; writing\u2014original draft preparation, A.B., G.D.S. and F.C.;\nwriting\u2014review and editing, P.D.G., M.L., P.C. and M.M. All authors have read\nand agreed to the published version of the manuscript.\n\nGo to:\n\n## Institutional Review Board Statement\n\nThe study was conducted in accordance with the Declaration of Helsinki and\napproved by the Ethics Committee of Fondazione Policlinico Gemelli IRCCS.\n\nGo to:\n\n## Informed Consent Statement\n\nInformed consent was obtained from all subjects involved in the study.\n\nGo to:\n\n## Data Availability Statement\n\nThe datasets analysed during the current study are available from the\ncorresponding author upon reasonable request.\n\nGo to:\n\n## Conflicts of Interest\n\nA.B. has served on advisory boards and/or has received travel grants and/or\nspeaker honoraria from Merck, Biogen, Almirall, Novartis, and Sanof-Genzyme.\nM.L. has served on advisory boards and/or has received travel grants and/or\nspeaker honoraria from Merck, Biogen, Almirall, Novartis, and Sanof-Genzyme.\nM.M.: scientific advisory board membership of Bayer Schering, Biogen, Sanof-\nGenzyme, Merck, Novartis, and Teva; consulting and/or speaking fees, research\nsupport, or travel grants from Almirall, Bayer Schering, Biogen, CSL Behring,\nSanof-Genzyme, Merck, Novartis, Teva, Roche, and Ultragenix; and principal\ninvestigator in clinical trials for Biogen, Merck, Novartis, Roche, Sanof\nGenzyme, Teva, Ultragenix, and CSL Behring. Other authors have nothing to\ndeclare.\n\nGo to:\n\n## Footnotes\n\nDisclaimer/Publisher\u2019s Note: The statements, opinions and data contained in\nall publications are solely those of the individual author(s) and\ncontributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)\ndisclaim responsibility for any injury to people or property resulting from\nany ideas, methods, instructions or products referred to in the content.\n\nGo to:\n\n## References\n\n1\\. Ascherio A. Environmental Factors in Multiple Sclerosis. Expert Rev.\nNeurother. 2013;13:3\u20139. doi: 10.1586/14737175.2013.865866. [PubMed] [CrossRef]\n[Google Scholar]\n\n2\\. Baecher-Allan C., Kaskow B.J., Weiner H.L. Multiple Sclerosis: Mechanisms\nand Immunotherapy. Neuron. 2018;97:742\u2013768. doi: 10.1016/j.neuron.2018.01.021.\n[PubMed] [CrossRef] [Google Scholar]\n\n3\\. Dendrou C.A., Fugger L., Friese M.A. Immunopathology of Multiple\nSclerosis. Nat. Rev. Immunol. 2015;15:545\u2013558. doi: 10.1038/nri3871. [PubMed]\n[CrossRef] [Google Scholar]\n\n4\\. Bordi I., Ricigliano V.A.G., Umeton R., Ristori G., Grassi F., Crisanti\nA., Sutera A., Salvetti M. Noise in Multiple Sclerosis: Unwanted and\nNecessary. Ann. Clin. Transl. Neurol. 2014;1:502\u2013511. doi: 10.1002/acn3.72.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n5\\. Kakalacheva K., M\u00fcnz C., L\u00fcnemann J.D. Viral Triggers of Multiple\nSclerosis. Biochim. Biophys. Acta. 2011;1812:132\u2013140. doi:\n10.1016/j.bbadis.2010.06.012. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n6\\. Ricigliano V.A.G., Handel A.E., Sandve G.K., Annibali V., Ristori G.,\nMechelli R., Cader M.Z., Salvetti M. EBNA2 Binds to Genomic Intervals\nAssociated with Multiple Sclerosis and Overlaps with Vitamin D Receptor\nOccupancy. PLoS ONE. 2015;10:e0119605. doi: 10.1371/journal.pone.0119605. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n7\\. Mechelli R., Romano C., Reni\u00e8 R., Manfr\u00e8 G., Buscarinu M.C., Romano S.,\nMarrone A., Bigi R., Bellucci G., Ballerini C., et al. Viruses and\nNeuroinflammation in Multiple Sclerosis. Neurosciences. 2021;8:269. doi:\n10.20517/2347-8659.2021.01. [CrossRef] [Google Scholar]\n\n8\\. Frau J., Coghe G., Lorefice L., Fenu G., Cocco E. Infections and Multiple\nSclerosis: From the World to Sardinia, from Sardinia to the World. Front.\nImmunol. 2021;12:728677. doi: 10.3389/fimmu.2021.728677. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n9\\. Bjornevik K., Cortese M., Healy B.C., Kuhle J., Mina M.J., Leng Y.,\nElledge S.J., Niebuhr D.W., Scher A.I., Munger K.L., et al. Longitudinal\nAnalysis Reveals High Prevalence of Epstein-Barr Virus Associated with\nMultiple Sclerosis. Science. 2022;375:296\u2013301. doi: 10.1126/science.abj8222.\n[PubMed] [CrossRef] [Google Scholar]\n\n10\\. Langer-Gould A., Qian L., Tartof S.Y., Brara S.M., Jacobsen S.J., Beaber\nB.E., Sy L.S., Chao C., Hechter R., Tseng H.F. Vaccines and the Risk of\nMultiple Sclerosis and Other Central Nervous System Demyelinating Diseases.\nJAMA Neurol. 2014;71:1506\u20131513. doi: 10.1001/jamaneurol.2014.2633. [PubMed]\n[CrossRef] [Google Scholar]\n\n11\\. Farez M.F., Correale J. Immunizations and Risk of Multiple Sclerosis:\nSystematic Review and Meta-Analysis. J. Neurol. 2011;258:1197\u20131206. doi:\n10.1007/s00415-011-5984-2. [PubMed] [CrossRef] [Google Scholar]\n\n12\\. Mailand M.T., Frederiksen J.L. Vaccines and Multiple Sclerosis: A\nSystematic Review. J. Neurol. 2017;264:1035\u20131050. doi:\n10.1007/s00415-016-8263-4. [PubMed] [CrossRef] [Google Scholar]\n\n13\\. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K.,\nAntoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.-E.,\nKatsaounou P., et al. Complex Immune Dysregulation in COVID-19 Patients with\nSevere Respiratory Failure. Cell Host Microbe. 2020;27:992\u20131000.e3. doi:\n10.1016/j.chom.2020.04.009. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n14\\. Subbarao K., Mahanty S. Respiratory Virus Infections: Understanding\nCOVID-19. Immunity. 2020;52:905\u2013909. doi: 10.1016/j.immuni.2020.05.004. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n15\\. McCuddy M., Kelkar P., Zhao Y., Wicklund D. Acute Demyelinating\nEncephalomyelitis (ADEM) in COVID-19 Infection: A Case Series. Neurol. India.\n2020;68:1192\u20131195. doi: 10.4103/0028-3886.299174. [PubMed] [CrossRef] [Google\nScholar]\n\n16\\. Novi G., Rossi T., Pedemonte E., Saitta L., Rolla C., Roccatagliata L.,\nInglese M., Farinini D. Acute Disseminated Encephalomyelitis after SARS-CoV-2\nInfection. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e797. doi:\n10.1212/NXI.0000000000000797. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n17\\. Shaw P.J., Barr M.J., Lukens J.R., McGargill M.A., Chi H., Mak T.W.,\nKanneganti T.-D. Signaling via the RIP2 Adaptor Protein in Central Nervous\nSystem-Infiltrating Dendritic Cells Promotes Inflammation and Autoimmunity.\nImmunity. 2011;34:75\u201384. doi: 10.1016/j.immuni.2010.12.015. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n18\\. Corr\u00eaa D.G., de Souza Lima F.C., da Cruz Bezerra D., Coutinho A.C.,\nHygino da Cruz L.C. COVID-19 Associated with Encephalomyeloradiculitis and\nPositive Anti-Aquaporin-4 Antibodies: Cause or Coincidence? Mult. Scler.\n2021;27:973\u2013976. doi: 10.1177/1352458520949988. [PubMed] [CrossRef] [Google\nScholar]\n\n19\\. Naser Moghadasi A. A 31-Year-Old Female Patient with Concurrent Clinical\nOnset of Multiple Sclerosis and COVID-19: Possible Role of SARS-CoV-2 in the\nPathogenesis of Multiple Sclerosis. Autoimmun. Rev. 2021;20:102803. doi:\n10.1016/j.autrev.2021.102803. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n20\\. Moore L., Ghannam M., Manousakis G. A First Presentation of Multiple\nSclerosis with Concurrent COVID-19 Infection. eNeurologicalSci.\n2021;22:100299. doi: 10.1016/j.ensci.2020.100299. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n21\\. Fragoso Y.D., Pacheco F.A.S., Silveira G.L., Oliveira R.A., Carvalho\nV.M., Martimbianco A.L.C. COVID-19 in a Temporal Relation to the Onset of\nMultiple Sclerosis. Mult. Scler. Relat. Disord. 2021;50:102863. doi:\n10.1016/j.msard.2021.102863. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n22\\. Palao M., Fern\u00e1ndez-D\u00edaz E., Gracia-Gil J., Romero-S\u00e1nchez C.M., D\u00edaz-\nMaroto I., Segura T. Multiple Sclerosis Following SARS-CoV-2 Infection. Mult.\nScler. Relat. Disord. 2020;45:102377. doi: 10.1016/j.msard.2020.102377. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n23\\. Lotan I., Nishiyama S., Manzano G.S., Lydston M., Levy M. COVID-19 and\nthe Risk of CNS Demyelinating Diseases: A Systematic Review. Front. Neurol.\n2022;13:970383. doi: 10.3389/fneur.2022.970383. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n24\\. Kaulen L.D., Doubrovinskaia S., Mooshage C., Jordan B., Purrucker J.,\nHaubner C., Seliger C., Lorenz H.-M., Nagel S., Wildemann B., et al.\nNeurological Autoimmune Diseases Following Vaccinations against SARS-CoV-2: A\nCase Series. Eur. J. Neurol. 2022;29:555\u2013563. doi: 10.1111/ene.15147. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n25\\. Li X., Ravent\u00f3s B., Roel E., Pistillo A., Martinez-Hernandez E.,\nDelmestri A., Reyes C., Strauss V., Prieto-Alhambra D., Burn E., et al.\nAssociation between Covid-19 Vaccination, SARS-CoV-2 Infection, and Risk of\nImmune Mediated Neurological Events: Population Based Cohort and Self-\nControlled Case Series Analysis. BMJ. 2022;376:e068373. doi:\n10.1136/bmj-2021-068373. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n26\\. Patone M., Handunnetthi L., Saatci D., Pan J., Katikireddi S.V., Razvi\nS., Hunt D., Mei X.W., Dixon S., Zaccardi F., et al. Neurological\nComplications after First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection.\nNat. Med. 2021;27:2144\u20132153. doi: 10.1038/s41591-021-01556-7. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n27\\. Bianco A., Col\u00f2 F., Falso S., Russo R., Carl\u00e0 M.M., Minucci A., Cadoni\nG., Lucchini M., Cicia A., Calabresi P., et al. New Onset of Susac Syndrome\nafter mRNA COVID-19 Vaccine: A Case Report. J. Neurol. 2023;270:614\u2013617. doi:\n10.1007/s00415-022-11406-2. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n28\\. Havla J., Schultz Y., Zimmermann H., Hohlfeld R., Danek A., K\u00fcmpfel T.\nFirst Manifestation of Multiple Sclerosis after Immunization with the Pfizer-\nBioNTech COVID-19 Vaccine. J. Neurol. 2022;269:55\u201358. doi:\n10.1007/s00415-021-10648-w. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n29\\. Khayat-Khoei M., Bhattacharyya S., Katz J., Harrison D., Tauhid S., Bruso\nP., Houtchens M.K., Edwards K.R., Bakshi R. COVID-19 mRNA Vaccination Leading\nto CNS Inflammation: A Case Series. J. Neurol. 2022;269:1093\u20131106. doi:\n10.1007/s00415-021-10780-7. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n30\\. Toljan K., Amin M., Kunchok A., Ontaneda D. New Diagnosis of Multiple\nSclerosis in the Setting of mRNA COVID-19 Vaccine Exposure. J. Neuroimmunol.\n2022;362:577785. doi: 10.1016/j.jneuroim.2021.577785. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n31\\. Alluqmani M. New Onset Multiple Sclerosis Post-COVID-19 Vaccination and\nCorrelation With Possible Predictors in a Case-Control Study. Cureus.\n2023;15:e36323. doi: 10.7759/cureus.36323. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n32\\. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley\nP.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and\nEfficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An\nInterim Analysis of Four Randomised Controlled Trials in Brazil, South Africa,\nand the UK. Lancet. 2021;397:99\u2013111. doi: 10.1016/S0140-6736(20)32661-1. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n33\\. Rinaldi V., Bellucci G., Buscarinu M.C., Reni\u00e8 R., Marrone A., Nasello\nM., Zancan V., Nistri R., Palumbo R., Salerno A., et al. CNS Inflammatory\nDemyelinating Events after COVID-19 Vaccines: A Case Series and Systematic\nReview. Front. Neurol. 2022;13:1018785. doi: 10.3389/fneur.2022.1018785. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n34\\. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar\nM., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., et al. A\nPredominant Role for the HLA Class II Region in the Association of the MHC\nRegion with Multiple Sclerosis. Nat. Genet. 2005;37:1108\u20131112. doi:\n10.1038/ng1647. [PubMed] [CrossRef] [Google Scholar]\n\n35\\. Ballerini C., Guerini F.R., Rombol\u00e0 G., Rosati E., Massacesi L., Ferrante\nP., Caputo D., Talamanca L.F., Naldi P., Liguori M., et al. HLA-Multiple\nSclerosis Association in Continental Italy and Correlation with Disease\nPrevalence in Europe. J. Neuroimmunol. 2004;150:178\u2013185. doi:\n10.1016/j.jneuroim.2004.01.015. [PubMed] [CrossRef] [Google Scholar]\n\n36\\. The International Multiple Sclerosis Genetics Consortium & The Wellcome\nTrust Case Control Consortium 2 Genetic Risk and a Primary Role for Cell-\nMediated Immune Mechanisms in Multiple Sclerosis. Nature. 2011;476:214\u2013219.\ndoi: 10.1038/nature10251. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n37\\. International Multiple Sclerosis Genetics Consortium. Patsopoulos N.A.,\nBaranzini S.E., Santaniello A., Shoostari P., Cotsapas C., Wong G., Beecham\nA.H., James T., Replogle J., et al. Multiple Sclerosis Genomic Map Implicates\nPeripheral Immune Cells and Microglia in Susceptibility. Science.\n2019;365:eaav7188. doi: 10.1126/science.aav7188. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n38\\. Li H., Hou X., Liang Y., Xu F., Zhang X., Cui P., Xing G., Wang X., Jiang\nW. Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel\nMultiple Sclerosis Risk Genes. Front. Neurosci. 2021;15:614528. doi:\n10.3389/fnins.2021.614528. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n39\\. Raine C.S. Multiple Sclerosis: Immune System Molecule Expression in the\nCentral Nervous System. J. Neuropathol. Exp. Neurol. 1994;53:328\u2013337. doi:\n10.1097/00005072-199407000-00002. [PubMed] [CrossRef] [Google Scholar]\n\n40\\. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A.\nIncreased Frequency of Interleukin 2-Responsive T Cells Specific for Myelin\nBasic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal\nFluid of Patients with Multiple Sclerosis. J. Exp. Med. 1994;179:973\u2013984. doi:\n10.1084/jem.179.3.973. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n41\\. Staun-Ram E., Miller A. Effector and Regulatory B Cells in Multiple\nSclerosis. Clin. Immunol. 2017;184:11\u201325. doi: 10.1016/j.clim.2017.04.014.\n[PubMed] [CrossRef] [Google Scholar]\n\n42\\. Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. B Cells and Antibodies in\nMultiple Sclerosis Pathogenesis and Therapy. Nat. Rev. Neurol. 2012;8:613\u2013623.\ndoi: 10.1038/nrneurol.2012.203. [PubMed] [CrossRef] [Google Scholar]\n\n43\\. Charo I.F., Ransohoff R.M. The Many Roles of Chemokines and Chemokine\nReceptors in Inflammation. N. Engl. J. Med. 2006;354:610\u2013621. doi:\n10.1056/NEJMra052723. [PubMed] [CrossRef] [Google Scholar]\n\n44\\. Bartholom\u00e4us I., Kawakami N., Odoardi F., Schl\u00e4ger C., Miljkovic D.,\nEllwart J.W., Klinkert W.E.F., Fl\u00fcgel-Koch C., Issekutz T.B., Wekerle H., et\nal. Effector T Cell Interactions with Meningeal Vascular Structures in Nascent\nAutoimmune CNS Lesions. Nature. 2009;462:94\u201398. doi: 10.1038/nature08478.\n[PubMed] [CrossRef] [Google Scholar]\n\n45\\. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer\nT., Noelle R.J., Becher B. Dendritic Cells Permit Immune Invasion of the CNS\nin an Animal Model of Multiple Sclerosis. Nat. Med. 2005;11:328\u2013334. doi:\n10.1038/nm1197. [PubMed] [CrossRef] [Google Scholar]\n\n46\\. Aloisi F., Ria F., Adorini L. Regulation of T-Cell Responses by CNS\nAntigen-Presenting Cells: Different Roles for Microglia and Astrocytes.\nImmunol. Today. 2000;21:141\u2013147. doi: 10.1016/S0167-5699(99)01512-1. [PubMed]\n[CrossRef] [Google Scholar]\n\n47\\. Tredicine M., Camponeschi C., Pirolli D., Lucchini M., Valentini M.,\nGeloso M.C., Mirabella M., Fidaleo M., Righino B., Moliterni C., et al. A\nTLR/CD44 Axis Regulates T Cell Trafficking in Experimental and Human Multiple\nSclerosis. iScience. 2022;25:103763. doi: 10.1016/j.isci.2022.103763. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar]\n\n48\\. Steinman L., Martin R., Bernard C., Conlon P., Oksenberg J.R. Multiple\nSclerosis: Deeper Understanding of Its Pathogenesis Reveals New Targets for\nTherapy. Annu. Rev. Neurosci. 2002;25:491\u2013505. doi:\n10.1146/annurev.neuro.25.112701.142913. [PubMed] [CrossRef] [Google Scholar]\n\n49\\. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., B\u00fcssow K., Sommer\nN., Hemmer B. Identification of Epstein-Barr Virus Proteins as Putative\nTargets of the Immune Response in Multiple Sclerosis. J. Clin. Investig.\n2005;115:1352\u20131360. doi: 10.1172/JCI200523661. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n50\\. Absinta M., Maric D., Gharagozloo M., Garton T., Smith M.D., Jin J.,\nFitzgerald K.C., Song A., Liu P., Lin J.-P., et al. A Lymphocyte-Microglia-\nAstrocyte Axis in Chronic Active Multiple Sclerosis. Nature. 2021;597:709\u2013714.\ndoi: 10.1038/s41586-021-03892-7. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar]\n\n51\\. Bell L., Koeniger T., Tacke S., Kuerten S. Characterization of\nBlood\u2013Brain Barrier Integrity in a B-Cell-Dependent Mouse Model of Multiple\nSclerosis. Histochem. Cell Biol. 2019;151:489\u2013499. doi:\n10.1007/s00418-019-01768-6. [PubMed] [CrossRef] [Google Scholar]\n\n52\\. Ebers G.C., Kukay K., Bulman D.E., Sadovnick A.D., Rice G., Anderson C.,\nArmstrong H., Cousin K., Bell R.B., Hader W., et al. A Full Genome Search in\nMultiple Sclerosis. Nat. Genet. 1996;13:472\u2013476. doi: 10.1038/ng0896-472.\n[PubMed] [CrossRef] [Google Scholar]\n\n53\\. Guo M.H., Sama P., LaBarre B.A., Lokhande H., Balibalos J., Chu C., Du\nX., Kheradpour P., Kim C.C., Oniskey T., et al. Dissection of Multiple\nSclerosis Genetics Identifies B and CD4+ T Cells as Driver Cell Subsets.\nGenome Biol. 2022;23:127. doi: 10.1186/s13059-022-02694-y. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n54\\. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R.,\nBernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 Lymphocytes\nPromote Blood-Brain Barrier Disruption and Central Nervous System\nInflammation. Nat. Med. 2007;13:1173\u20131175. doi: 10.1038/nm1651. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n55\\. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N.,\nDuquette P., Prat A. Preferential Recruitment of Interferon-\u03b3-Expressing T _H\n17 Cells in Multiple Sclerosis. Ann. Neurol. 2009;66:390\u2013402. doi:\n10.1002/ana.21748. [PubMed] [CrossRef] [Google Scholar]\n\n56\\. Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.-P., Hemmer B.,\nLublin F., Montalban X., Rammohan K.W., Selmaj K., et al. Ocrelizumab versus\nInterferon Beta-1a in Relapsing Multiple Sclerosis. N. Engl. J. Med.\n2017;376:221\u2013234. doi: 10.1056/NEJMoa1601277. [PubMed] [CrossRef] [Google\nScholar]\n\n57\\. Tavazzi E., Pichiecchio A., Colombo E., Rigoni E., Asteggiano C., Vegezzi\nE., Masi F., Greco G., Bastianello S., Bergamaschi R. The Potential Role of\nSARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and\nReactivation: A Case Series and Literature Review. Viruses. 2023;15:1569. doi:\n10.3390/v15071569. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n58\\. Harel T., Gorman E.F., Wallin M.T. New Onset or Relapsing Neuromyelitis\nOptica Temporally Associated with SARS-CoV-2 Infection and COVID-19\nVaccination: A Systematic Review. Front. Neurol. 2023;14:1099758. doi:\n10.3389/fneur.2023.1099758. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n59\\. Etemadifar M., Sigari A.A., Sedaghat N., Salari M., Nouri H. Acute\nRelapse and Poor Immunization Following COVID-19 Vaccination in a Rituximab-\nTreated Multiple Sclerosis Patient. Hum. Vaccines Immunother.\n2021;17:3481\u20133483. doi: 10.1080/21645515.2021.1928463. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n60\\. Maniscalco G.T., Manzo V., Di Battista M.E., Salvatore S., Moreggia O.,\nScavone C., Capuano A. Severe Multiple Sclerosis Relapse After COVID-19\nVaccination: A Case Report. Front. Neurol. 2021;12:721502. doi:\n10.3389/fneur.2021.721502. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n61\\. Gonzalez-Galarza F.F., McCabe A., Santos E.J.M.D., Jones J., Takeshita\nL., Ortega-Rivera N.D., Cid-Pavon G.M.D., Ramsbottom K., Ghattaoraya G.,\nAlfirevic A., et al. Allele Frequency Net Database (AFND) 2020 Update: Gold-\nStandard Data Classification, Open Access Genotype Data and New Query Tools.\nNucleic Acids Res. 2019;48:D783\u2013D788. doi: 10.1093/nar/gkz1029. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n62\\. Menges D., Zens K.D., Ballouz T., Caduff N., Llanas-Cornejo D., Aschmann\nH.E., Domenghino A., Pellaton C., Perreau M., Fenwick C., et al. Heterogenous\nHumoral and Cellular Immune Responses with Distinct Trajectories Post-SARS-\nCoV-2 Infection in a Population-Based Cohort. Nat. Commun. 2022;13:4855. doi:\n10.1038/s41467-022-32573-w. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n63\\. Carrat F., Villarroel P.M.S., Lapidus N., Fouri\u00e9 T., Blanch\u00e9 H., Dorival\nC., Nicol J., Deleuze J.-F., Robineau O., SAPRIS-SERO Study Group et al.\nHeterogeneous SARS-CoV-2 Humoral Response after COVID-19 Vaccination and/or\nInfection in the General Population. Sci. Rep. 2022;12:8622. doi:\n10.1038/s41598-022-11787-4. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n64\\. Garc\u00eda Borr\u00e1s S., Moreno J., Abraham N., Tanno H., Garc\u00eda Laplaca M.,\nRossi M.C., Racca L., Racca A. HLA-DRB1 as a Risk or Resistance Factor in\nAutoimmune Hepatitis. Inmunolog\u00eda. 2011;30:115\u2013118. doi:\n10.1016/j.inmuno.2011.07.003. [CrossRef] [Google Scholar]\n\n65\\. The International Multiple Sclerosis Genetics Consortium Class II HLA\nInteractions Modulate Genetic Risk for Multiple Sclerosis. Nat. Genet.\n2015;47:1107\u20131113. doi: 10.1038/ng.3395. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n66\\. Mu\u00f1iz-Castrillo S., Vogrig A., Honnorat J. Associations between HLA and\nAutoimmune Neurological Diseases with Autoantibodies. Autoimmun. Highlights.\n2020;11:2. doi: 10.1186/s13317-019-0124-6. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n67\\. Guimara\u00e3es Brum D., Barreira A.A., Dos Santos A.C., Kaimen-Maciel D.R.,\nMatiello M., Costa R.M., Saloun Deghaide N.H., Silva Costa L., Louzada-Junior\nP., Beserra Diniz P.R., et al. HLA-DRB Association in Neuromyelitis Optica Is\nDifferent from That Observed in Multiple Sclerosis. Mult. Scler.\n2010;16:21\u201329. doi: 10.1177/1352458509350741. [PubMed] [CrossRef] [Google\nScholar]\n\n68\\. Alonso V.R., De Jesus Flores Rivera J., Garci Y.R., Granados J., Sanchez\nT., Mena-Hernandez L., Corona T. Neuromyelitis Optica (NMO IgG+) and Genetic\nSusceptibility, Potential Ethnic Influences. Central Nerv. Syst. Agents Med.\nChem. 2018;18:4\u20137. doi: 10.2174/1871524916666160229115047. [PubMed] [CrossRef]\n[Google Scholar]\n\n69\\. Deschamps R., Paturel L., Jeannin S., Chausson N., Olindo S., B\u00e9ra O.,\nBellance R., Smadja D., C\u00e9saire D., Cabre P. Different HLA Class II (DRB1 and\nDQB1) Alleles Determine Either Susceptibility or Resistance to NMO and\nMultiple Sclerosis among the French Afro-Caribbean Population. Mult. Scler.\n2011;17:24\u201331. doi: 10.1177/1352458510382810. [PubMed] [CrossRef] [Google\nScholar]\n\n70\\. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi\nG., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of\nMultiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol.\n2018;17:162\u2013173. doi: 10.1016/S1474-4422(17)30470-2. [PubMed] [CrossRef]\n[Google Scholar]\n\n71\\. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart\nS., Perez J.L., P\u00e9rez Marc G., Moreira E.D., Zerbini C., et al. Safety and\nEfficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med.\n2020;383:2603\u20132615. doi: 10.1056/NEJMoa2034577. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n72\\. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R.,\nDiemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety\nof the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403\u2013416. doi:\n10.1056/NEJMoa2035389. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n\n73\\. Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-\nRammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al.\nSafety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine against SARS-CoV-2: A\nPreliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial.\nLancet. 2020;396:467\u2013478. doi: 10.1016/S0140-6736(20)31604-4. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar]\n\n74\\. Sadoff J., Gray G., Vandebosch A., C\u00e1rdenas V., Shukarev G., Grinsztejn\nB., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and\nEfficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med.\n2021;384:2187\u20132201. doi: 10.1056/NEJMoa2101544. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n75\\. Herman C., Mayer K., Sarwal A. Scoping Review of Prevalence of Neurologic\nComorbidities in Patients Hospitalized for COVID-19. Neurology. 2020;95:77\u201384.\ndoi: 10.1212/WNL.0000000000009673. [PubMed] [CrossRef] [Google Scholar]\n\n76\\. [(accessed on 10 March 2024)]. Available online:\nhttps://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-\nupdate/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-\nastrazeneca-14-april-2021_en.pdf\n\n77\\. Spagni G., Todi L., Monte G., Valentini M., Di Sante G., Damato V.,\nMarino M., Evoli A., Lantieri F., Provenzano C. Human Leukocyte Antigen Class\nII Associations in Late-Onset Myasthenia Gravis. Ann. Clin. Transl. Neurol.\n2021;8:656\u2013665. doi: 10.1002/acn3.51309. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar]\n\n78\\. Di Sante G., Tolusso B., Fedele A.L., Gremese E., Alivernini S., Nicol\u00f2\nC., Ria F., Ferraccioli G. Collagen Specific T-Cell Repertoire and HLA-DR\nAlleles: Biomarkers of Active Refractory Rheumatoid Arthritis. eBioMedicine.\n2015;2:2037\u20132045. doi: 10.1016/j.ebiom.2015.11.019. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n79\\. Marino M., Maiuri M.T., Di Sante G., Scuderi F., La Carpia F., Trakas N.,\nProvenzano C., Zisimopoulou P., Ria F., Tzartos S.J., et al. T Cell Repertoire\nin DQ5-Positive MuSK-Positive Myasthenia Gravis Patients. J. Autoimmun.\n2014;52:113\u2013121. doi: 10.1016/j.jaut.2013.12.007. [PubMed] [CrossRef] [Google\nScholar]\n\n80\\. Di Sante G., Gremese E., Tolusso B., Cattani P., Di Mario C., Marchetti\nS., Alivernini S., Tredicine M., Petricca L., Palucci I., et al. Haemophilus\nParasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry\nand Inflammation in Rheumatoid Arthritis. Front. Med. 2021;8:671018. doi:\n10.3389/fmed.2021.671018. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n81\\. Confavreux C., Suissa S., Saddier P., Bourd\u00e8s V., Vukusic S., Vaccines in\nMultiple Sclerosis Study Group Vaccinations and the Risk of Relapse in\nMultiple Sclerosis Vaccines in Multiple Sclerosis Study Group. N. Engl. J.\nMed. 2001;344:319\u2013326. doi: 10.1056/NEJM200102013440501. [PubMed] [CrossRef]\n[Google Scholar]\n\n82\\. Olsson T., Barcellos L.F., Alfredsson L. Interactions between Genetic,\nLifestyle and Environmental Risk Factors for Multiple Sclerosis. Nat. Rev.\nNeurol. 2017;13:25\u201336. doi: 10.1038/nrneurol.2016.187. [PubMed] [CrossRef]\n[Google Scholar]\n\n83\\. Alfredsson L., Olsson T. Lifestyle and Environmental Factors in Multiple\nSclerosis. Cold Spring Harb. Perspect. Med. 2019;9:a028944. doi:\n10.1101/cshperspect.a028944. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n84\\. Goodin D.S., Khankhanian P., Gourraud P.-A., Vince N. The Nature of\nGenetic and Environmental Susceptibility to Multiple Sclerosis. PLoS ONE.\n2021;16:e0246157. doi: 10.1371/journal.pone.0246157. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar]\n\n85\\. Pandolfi F., Cianci R., Casciano F., Pagliari D., De Pasquale T.,\nLandolfi R., Di Sante G., Kurnick J.T., Ria F. Skewed T-Cell Receptor\nRepertoire: More than a Marker of Malignancy, a Tool to Dissect the\nImmunopathology of Inflammatory Diseases. J. Biol. Regul. Homeost. Agents.\n2011;25:153\u2013161. [PubMed] [Google Scholar]\n\n86\\. Nicol\u00f2 C., Di Sante G., Procoli A., Migliara G., Piermattei A., Valentini\nM., Delogu G., Cittadini A., Constantin G., Ria F. M tuberculosis in the\nAdjuvant Modulates Time of Appearance of CNS-Specific Effector T Cells in the\nSpleen through a Polymorphic Site of TLR2. PLoS ONE. 2013;8:e55819. doi:\n10.1371/journal.pone.0055819. [PMC free article] [PubMed] [CrossRef] [Google\nScholar]\n\n  * Abstract\n  * 1\\. Introduction\n  * 2\\. Results\n  * 3\\. Discussion\n  * 4\\. Materials and Methods\n  * 5\\. Conclusions\n  * Supplementary Materials\n  * Funding Statement\n  * Author Contributions\n  * Institutional Review Board Statement\n  * Informed Consent Statement\n  * Data Availability Statement\n  * Conflicts of Interest\n  * Footnotes\n  * References\n\nArticles from International Journal of Molecular Sciences are provided here\ncourtesy of Multidisciplinary Digital Publishing Institute (MDPI)\n\n1\\. Ascherio A. Environmental Factors in Multiple Sclerosis. Expert Rev.\nNeurother. 2013;13:3\u20139. doi: 10.1586/14737175.2013.865866. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n2\\. Baecher-Allan C., Kaskow B.J., Weiner H.L. Multiple Sclerosis: Mechanisms\nand Immunotherapy. Neuron. 2018;97:742\u2013768. doi: 10.1016/j.neuron.2018.01.021.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n3\\. Dendrou C.A., Fugger L., Friese M.A. Immunopathology of Multiple\nSclerosis. Nat. Rev. Immunol. 2015;15:545\u2013558. doi: 10.1038/nri3871. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n4\\. Bordi I., Ricigliano V.A.G., Umeton R., Ristori G., Grassi F., Crisanti\nA., Sutera A., Salvetti M. Noise in Multiple Sclerosis: Unwanted and\nNecessary. Ann. Clin. Transl. Neurol. 2014;1:502\u2013511. doi: 10.1002/acn3.72.\n[PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n5\\. Kakalacheva K., M\u00fcnz C., L\u00fcnemann J.D. Viral Triggers of Multiple\nSclerosis. Biochim. Biophys. Acta. 2011;1812:132\u2013140. doi:\n10.1016/j.bbadis.2010.06.012. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n6\\. Ricigliano V.A.G., Handel A.E., Sandve G.K., Annibali V., Ristori G.,\nMechelli R., Cader M.Z., Salvetti M. EBNA2 Binds to Genomic Intervals\nAssociated with Multiple Sclerosis and Overlaps with Vitamin D Receptor\nOccupancy. PLoS ONE. 2015;10:e0119605. doi: 10.1371/journal.pone.0119605. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n7\\. Mechelli R., Romano C., Reni\u00e8 R., Manfr\u00e8 G., Buscarinu M.C., Romano S.,\nMarrone A., Bigi R., Bellucci G., Ballerini C., et al. Viruses and\nNeuroinflammation in Multiple Sclerosis. Neurosciences. 2021;8:269. doi:\n10.20517/2347-8659.2021.01. [CrossRef] [Google Scholar] [Ref list]\n\n8\\. Frau J., Coghe G., Lorefice L., Fenu G., Cocco E. Infections and Multiple\nSclerosis: From the World to Sardinia, from Sardinia to the World. Front.\nImmunol. 2021;12:728677. doi: 10.3389/fimmu.2021.728677. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n9\\. Bjornevik K., Cortese M., Healy B.C., Kuhle J., Mina M.J., Leng Y.,\nElledge S.J., Niebuhr D.W., Scher A.I., Munger K.L., et al. Longitudinal\nAnalysis Reveals High Prevalence of Epstein-Barr Virus Associated with\nMultiple Sclerosis. Science. 2022;375:296\u2013301. doi: 10.1126/science.abj8222.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n10\\. Langer-Gould A., Qian L., Tartof S.Y., Brara S.M., Jacobsen S.J., Beaber\nB.E., Sy L.S., Chao C., Hechter R., Tseng H.F. Vaccines and the Risk of\nMultiple Sclerosis and Other Central Nervous System Demyelinating Diseases.\nJAMA Neurol. 2014;71:1506\u20131513. doi: 10.1001/jamaneurol.2014.2633. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n11\\. Farez M.F., Correale J. Immunizations and Risk of Multiple Sclerosis:\nSystematic Review and Meta-Analysis. J. Neurol. 2011;258:1197\u20131206. doi:\n10.1007/s00415-011-5984-2. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n12\\. Mailand M.T., Frederiksen J.L. Vaccines and Multiple Sclerosis: A\nSystematic Review. J. Neurol. 2017;264:1035\u20131050. doi:\n10.1007/s00415-016-8263-4. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n13\\. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K.,\nAntoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.-E.,\nKatsaounou P., et al. Complex Immune Dysregulation in COVID-19 Patients with\nSevere Respiratory Failure. Cell Host Microbe. 2020;27:992\u20131000.e3. doi:\n10.1016/j.chom.2020.04.009. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n14\\. Subbarao K., Mahanty S. Respiratory Virus Infections: Understanding\nCOVID-19. Immunity. 2020;52:905\u2013909. doi: 10.1016/j.immuni.2020.05.004. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n15\\. McCuddy M., Kelkar P., Zhao Y., Wicklund D. Acute Demyelinating\nEncephalomyelitis (ADEM) in COVID-19 Infection: A Case Series. Neurol. India.\n2020;68:1192\u20131195. doi: 10.4103/0028-3886.299174. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n16\\. Novi G., Rossi T., Pedemonte E., Saitta L., Rolla C., Roccatagliata L.,\nInglese M., Farinini D. Acute Disseminated Encephalomyelitis after SARS-CoV-2\nInfection. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e797. doi:\n10.1212/NXI.0000000000000797. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n17\\. Shaw P.J., Barr M.J., Lukens J.R., McGargill M.A., Chi H., Mak T.W.,\nKanneganti T.-D. Signaling via the RIP2 Adaptor Protein in Central Nervous\nSystem-Infiltrating Dendritic Cells Promotes Inflammation and Autoimmunity.\nImmunity. 2011;34:75\u201384. doi: 10.1016/j.immuni.2010.12.015. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n18\\. Corr\u00eaa D.G., de Souza Lima F.C., da Cruz Bezerra D., Coutinho A.C.,\nHygino da Cruz L.C. COVID-19 Associated with Encephalomyeloradiculitis and\nPositive Anti-Aquaporin-4 Antibodies: Cause or Coincidence? Mult. Scler.\n2021;27:973\u2013976. doi: 10.1177/1352458520949988. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n19\\. Naser Moghadasi A. A 31-Year-Old Female Patient with Concurrent Clinical\nOnset of Multiple Sclerosis and COVID-19: Possible Role of SARS-CoV-2 in the\nPathogenesis of Multiple Sclerosis. Autoimmun. Rev. 2021;20:102803. doi:\n10.1016/j.autrev.2021.102803. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n20\\. Moore L., Ghannam M., Manousakis G. A First Presentation of Multiple\nSclerosis with Concurrent COVID-19 Infection. eNeurologicalSci.\n2021;22:100299. doi: 10.1016/j.ensci.2020.100299. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n21\\. Fragoso Y.D., Pacheco F.A.S., Silveira G.L., Oliveira R.A., Carvalho\nV.M., Martimbianco A.L.C. COVID-19 in a Temporal Relation to the Onset of\nMultiple Sclerosis. Mult. Scler. Relat. Disord. 2021;50:102863. doi:\n10.1016/j.msard.2021.102863. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n22\\. Palao M., Fern\u00e1ndez-D\u00edaz E., Gracia-Gil J., Romero-S\u00e1nchez C.M., D\u00edaz-\nMaroto I., Segura T. Multiple Sclerosis Following SARS-CoV-2 Infection. Mult.\nScler. Relat. Disord. 2020;45:102377. doi: 10.1016/j.msard.2020.102377. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n23\\. Lotan I., Nishiyama S., Manzano G.S., Lydston M., Levy M. COVID-19 and\nthe Risk of CNS Demyelinating Diseases: A Systematic Review. Front. Neurol.\n2022;13:970383. doi: 10.3389/fneur.2022.970383. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n24\\. Kaulen L.D., Doubrovinskaia S., Mooshage C., Jordan B., Purrucker J.,\nHaubner C., Seliger C., Lorenz H.-M., Nagel S., Wildemann B., et al.\nNeurological Autoimmune Diseases Following Vaccinations against SARS-CoV-2: A\nCase Series. Eur. J. Neurol. 2022;29:555\u2013563. doi: 10.1111/ene.15147. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n25\\. Li X., Ravent\u00f3s B., Roel E., Pistillo A., Martinez-Hernandez E.,\nDelmestri A., Reyes C., Strauss V., Prieto-Alhambra D., Burn E., et al.\nAssociation between Covid-19 Vaccination, SARS-CoV-2 Infection, and Risk of\nImmune Mediated Neurological Events: Population Based Cohort and Self-\nControlled Case Series Analysis. BMJ. 2022;376:e068373. doi:\n10.1136/bmj-2021-068373. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n26\\. Patone M., Handunnetthi L., Saatci D., Pan J., Katikireddi S.V., Razvi\nS., Hunt D., Mei X.W., Dixon S., Zaccardi F., et al. Neurological\nComplications after First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection.\nNat. Med. 2021;27:2144\u20132153. doi: 10.1038/s41591-021-01556-7. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n27\\. Bianco A., Col\u00f2 F., Falso S., Russo R., Carl\u00e0 M.M., Minucci A., Cadoni\nG., Lucchini M., Cicia A., Calabresi P., et al. New Onset of Susac Syndrome\nafter mRNA COVID-19 Vaccine: A Case Report. J. Neurol. 2023;270:614\u2013617. doi:\n10.1007/s00415-022-11406-2. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n28\\. Havla J., Schultz Y., Zimmermann H., Hohlfeld R., Danek A., K\u00fcmpfel T.\nFirst Manifestation of Multiple Sclerosis after Immunization with the Pfizer-\nBioNTech COVID-19 Vaccine. J. Neurol. 2022;269:55\u201358. doi:\n10.1007/s00415-021-10648-w. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n29\\. Khayat-Khoei M., Bhattacharyya S., Katz J., Harrison D., Tauhid S., Bruso\nP., Houtchens M.K., Edwards K.R., Bakshi R. COVID-19 mRNA Vaccination Leading\nto CNS Inflammation: A Case Series. J. Neurol. 2022;269:1093\u20131106. doi:\n10.1007/s00415-021-10780-7. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n30\\. Toljan K., Amin M., Kunchok A., Ontaneda D. New Diagnosis of Multiple\nSclerosis in the Setting of mRNA COVID-19 Vaccine Exposure. J. Neuroimmunol.\n2022;362:577785. doi: 10.1016/j.jneuroim.2021.577785. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n31\\. Alluqmani M. New Onset Multiple Sclerosis Post-COVID-19 Vaccination and\nCorrelation With Possible Predictors in a Case-Control Study. Cureus.\n2023;15:e36323. doi: 10.7759/cureus.36323. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n32\\. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley\nP.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and\nEfficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An\nInterim Analysis of Four Randomised Controlled Trials in Brazil, South Africa,\nand the UK. Lancet. 2021;397:99\u2013111. doi: 10.1016/S0140-6736(20)32661-1. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n33\\. Rinaldi V., Bellucci G., Buscarinu M.C., Reni\u00e8 R., Marrone A., Nasello\nM., Zancan V., Nistri R., Palumbo R., Salerno A., et al. CNS Inflammatory\nDemyelinating Events after COVID-19 Vaccines: A Case Series and Systematic\nReview. Front. Neurol. 2022;13:1018785. doi: 10.3389/fneur.2022.1018785. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n34\\. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar\nM., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., et al. A\nPredominant Role for the HLA Class II Region in the Association of the MHC\nRegion with Multiple Sclerosis. Nat. Genet. 2005;37:1108\u20131112. doi:\n10.1038/ng1647. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n35\\. Ballerini C., Guerini F.R., Rombol\u00e0 G., Rosati E., Massacesi L., Ferrante\nP., Caputo D., Talamanca L.F., Naldi P., Liguori M., et al. HLA-Multiple\nSclerosis Association in Continental Italy and Correlation with Disease\nPrevalence in Europe. J. Neuroimmunol. 2004;150:178\u2013185. doi:\n10.1016/j.jneuroim.2004.01.015. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n36\\. The International Multiple Sclerosis Genetics Consortium & The Wellcome\nTrust Case Control Consortium 2 Genetic Risk and a Primary Role for Cell-\nMediated Immune Mechanisms in Multiple Sclerosis. Nature. 2011;476:214\u2013219.\ndoi: 10.1038/nature10251. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n37\\. International Multiple Sclerosis Genetics Consortium. Patsopoulos N.A.,\nBaranzini S.E., Santaniello A., Shoostari P., Cotsapas C., Wong G., Beecham\nA.H., James T., Replogle J., et al. Multiple Sclerosis Genomic Map Implicates\nPeripheral Immune Cells and Microglia in Susceptibility. Science.\n2019;365:eaav7188. doi: 10.1126/science.aav7188. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n38\\. Li H., Hou X., Liang Y., Xu F., Zhang X., Cui P., Xing G., Wang X., Jiang\nW. Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel\nMultiple Sclerosis Risk Genes. Front. Neurosci. 2021;15:614528. doi:\n10.3389/fnins.2021.614528. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n39\\. Raine C.S. Multiple Sclerosis: Immune System Molecule Expression in the\nCentral Nervous System. J. Neuropathol. Exp. Neurol. 1994;53:328\u2013337. doi:\n10.1097/00005072-199407000-00002. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n40\\. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A.\nIncreased Frequency of Interleukin 2-Responsive T Cells Specific for Myelin\nBasic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal\nFluid of Patients with Multiple Sclerosis. J. Exp. Med. 1994;179:973\u2013984. doi:\n10.1084/jem.179.3.973. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n41\\. Staun-Ram E., Miller A. Effector and Regulatory B Cells in Multiple\nSclerosis. Clin. Immunol. 2017;184:11\u201325. doi: 10.1016/j.clim.2017.04.014.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n42\\. Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. B Cells and Antibodies in\nMultiple Sclerosis Pathogenesis and Therapy. Nat. Rev. Neurol. 2012;8:613\u2013623.\ndoi: 10.1038/nrneurol.2012.203. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n43\\. Charo I.F., Ransohoff R.M. The Many Roles of Chemokines and Chemokine\nReceptors in Inflammation. N. Engl. J. Med. 2006;354:610\u2013621. doi:\n10.1056/NEJMra052723. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n44\\. Bartholom\u00e4us I., Kawakami N., Odoardi F., Schl\u00e4ger C., Miljkovic D.,\nEllwart J.W., Klinkert W.E.F., Fl\u00fcgel-Koch C., Issekutz T.B., Wekerle H., et\nal. Effector T Cell Interactions with Meningeal Vascular Structures in Nascent\nAutoimmune CNS Lesions. Nature. 2009;462:94\u201398. doi: 10.1038/nature08478.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n45\\. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer\nT., Noelle R.J., Becher B. Dendritic Cells Permit Immune Invasion of the CNS\nin an Animal Model of Multiple Sclerosis. Nat. Med. 2005;11:328\u2013334. doi:\n10.1038/nm1197. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n46\\. Aloisi F., Ria F., Adorini L. Regulation of T-Cell Responses by CNS\nAntigen-Presenting Cells: Different Roles for Microglia and Astrocytes.\nImmunol. Today. 2000;21:141\u2013147. doi: 10.1016/S0167-5699(99)01512-1. [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n47\\. Tredicine M., Camponeschi C., Pirolli D., Lucchini M., Valentini M.,\nGeloso M.C., Mirabella M., Fidaleo M., Righino B., Moliterni C., et al. A\nTLR/CD44 Axis Regulates T Cell Trafficking in Experimental and Human Multiple\nSclerosis. iScience. 2022;25:103763. doi: 10.1016/j.isci.2022.103763. [PMC\nfree article] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n48\\. Steinman L., Martin R., Bernard C., Conlon P., Oksenberg J.R. Multiple\nSclerosis: Deeper Understanding of Its Pathogenesis Reveals New Targets for\nTherapy. Annu. Rev. Neurosci. 2002;25:491\u2013505. doi:\n10.1146/annurev.neuro.25.112701.142913. [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n49\\. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., B\u00fcssow K., Sommer\nN., Hemmer B. Identification of Epstein-Barr Virus Proteins as Putative\nTargets of the Immune Response in Multiple Sclerosis. J. Clin. Investig.\n2005;115:1352\u20131360. doi: 10.1172/JCI200523661. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n50\\. Absinta M., Maric D., Gharagozloo M., Garton T., Smith M.D., Jin J.,\nFitzgerald K.C., Song A., Liu P., Lin J.-P., et al. A Lymphocyte-Microglia-\nAstrocyte Axis in Chronic Active Multiple Sclerosis. Nature. 2021;597:709\u2013714.\ndoi: 10.1038/s41586-021-03892-7. [PMC free article] [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n51\\. Bell L., Koeniger T., Tacke S., Kuerten S. Characterization of\nBlood\u2013Brain Barrier Integrity in a B-Cell-Dependent Mouse Model of Multiple\nSclerosis. Histochem. Cell Biol. 2019;151:489\u2013499. doi:\n10.1007/s00418-019-01768-6. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n52\\. Ebers G.C., Kukay K., Bulman D.E., Sadovnick A.D., Rice G., Anderson C.,\nArmstrong H., Cousin K., Bell R.B., Hader W., et al. A Full Genome Search in\nMultiple Sclerosis. Nat. Genet. 1996;13:472\u2013476. doi: 10.1038/ng0896-472.\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n53\\. Guo M.H., Sama P., LaBarre B.A., Lokhande H., Balibalos J., Chu C., Du\nX., Kheradpour P., Kim C.C., Oniskey T., et al. Dissection of Multiple\nSclerosis Genetics Identifies B and CD4+ T Cells as Driver Cell Subsets.\nGenome Biol. 2022;23:127. doi: 10.1186/s13059-022-02694-y. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n54\\. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R.,\nBernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 Lymphocytes\nPromote Blood-Brain Barrier Disruption and Central Nervous System\nInflammation. Nat. Med. 2007;13:1173\u20131175. doi: 10.1038/nm1651. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n55\\. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N.,\nDuquette P., Prat A. Preferential Recruitment of Interferon-\u03b3-Expressing T _H\n17 Cells in Multiple Sclerosis. Ann. Neurol. 2009;66:390\u2013402. doi:\n10.1002/ana.21748. [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n56\\. Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.-P., Hemmer B.,\nLublin F., Montalban X., Rammohan K.W., Selmaj K., et al. Ocrelizumab versus\nInterferon Beta-1a in Relapsing Multiple Sclerosis. N. Engl. J. Med.\n2017;376:221\u2013234. doi: 10.1056/NEJMoa1601277. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n57\\. Tavazzi E., Pichiecchio A., Colombo E., Rigoni E., Asteggiano C., Vegezzi\nE., Masi F., Greco G., Bastianello S., Bergamaschi R. The Potential Role of\nSARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and\nReactivation: A Case Series and Literature Review. Viruses. 2023;15:1569. doi:\n10.3390/v15071569. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n58\\. Harel T., Gorman E.F., Wallin M.T. New Onset or Relapsing Neuromyelitis\nOptica Temporally Associated with SARS-CoV-2 Infection and COVID-19\nVaccination: A Systematic Review. Front. Neurol. 2023;14:1099758. doi:\n10.3389/fneur.2023.1099758. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n59\\. Etemadifar M., Sigari A.A., Sedaghat N., Salari M., Nouri H. Acute\nRelapse and Poor Immunization Following COVID-19 Vaccination in a Rituximab-\nTreated Multiple Sclerosis Patient. Hum. Vaccines Immunother.\n2021;17:3481\u20133483. doi: 10.1080/21645515.2021.1928463. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n60\\. Maniscalco G.T., Manzo V., Di Battista M.E., Salvatore S., Moreggia O.,\nScavone C., Capuano A. Severe Multiple Sclerosis Relapse After COVID-19\nVaccination: A Case Report. Front. Neurol. 2021;12:721502. doi:\n10.3389/fneur.2021.721502. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n61\\. Gonzalez-Galarza F.F., McCabe A., Santos E.J.M.D., Jones J., Takeshita\nL., Ortega-Rivera N.D., Cid-Pavon G.M.D., Ramsbottom K., Ghattaoraya G.,\nAlfirevic A., et al. Allele Frequency Net Database (AFND) 2020 Update: Gold-\nStandard Data Classification, Open Access Genotype Data and New Query Tools.\nNucleic Acids Res. 2019;48:D783\u2013D788. doi: 10.1093/nar/gkz1029. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n62\\. Menges D., Zens K.D., Ballouz T., Caduff N., Llanas-Cornejo D., Aschmann\nH.E., Domenghino A., Pellaton C., Perreau M., Fenwick C., et al. Heterogenous\nHumoral and Cellular Immune Responses with Distinct Trajectories Post-SARS-\nCoV-2 Infection in a Population-Based Cohort. Nat. Commun. 2022;13:4855. doi:\n10.1038/s41467-022-32573-w. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n63\\. Carrat F., Villarroel P.M.S., Lapidus N., Fouri\u00e9 T., Blanch\u00e9 H., Dorival\nC., Nicol J., Deleuze J.-F., Robineau O., SAPRIS-SERO Study Group et al.\nHeterogeneous SARS-CoV-2 Humoral Response after COVID-19 Vaccination and/or\nInfection in the General Population. Sci. Rep. 2022;12:8622. doi:\n10.1038/s41598-022-11787-4. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n64\\. Garc\u00eda Borr\u00e1s S., Moreno J., Abraham N., Tanno H., Garc\u00eda Laplaca M.,\nRossi M.C., Racca L., Racca A. HLA-DRB1 as a Risk or Resistance Factor in\nAutoimmune Hepatitis. Inmunolog\u00eda. 2011;30:115\u2013118. doi:\n10.1016/j.inmuno.2011.07.003. [CrossRef] [Google Scholar] [Ref list]\n\n65\\. The International Multiple Sclerosis Genetics Consortium Class II HLA\nInteractions Modulate Genetic Risk for Multiple Sclerosis. Nat. Genet.\n2015;47:1107\u20131113. doi: 10.1038/ng.3395. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n66\\. Mu\u00f1iz-Castrillo S., Vogrig A., Honnorat J. Associations between HLA and\nAutoimmune Neurological Diseases with Autoantibodies. Autoimmun. Highlights.\n2020;11:2. doi: 10.1186/s13317-019-0124-6. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n67\\. Guimara\u00e3es Brum D., Barreira A.A., Dos Santos A.C., Kaimen-Maciel D.R.,\nMatiello M., Costa R.M., Saloun Deghaide N.H., Silva Costa L., Louzada-Junior\nP., Beserra Diniz P.R., et al. HLA-DRB Association in Neuromyelitis Optica Is\nDifferent from That Observed in Multiple Sclerosis. Mult. Scler.\n2010;16:21\u201329. doi: 10.1177/1352458509350741. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n68\\. Alonso V.R., De Jesus Flores Rivera J., Garci Y.R., Granados J., Sanchez\nT., Mena-Hernandez L., Corona T. Neuromyelitis Optica (NMO IgG+) and Genetic\nSusceptibility, Potential Ethnic Influences. Central Nerv. Syst. Agents Med.\nChem. 2018;18:4\u20137. doi: 10.2174/1871524916666160229115047. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n69\\. Deschamps R., Paturel L., Jeannin S., Chausson N., Olindo S., B\u00e9ra O.,\nBellance R., Smadja D., C\u00e9saire D., Cabre P. Different HLA Class II (DRB1 and\nDQB1) Alleles Determine Either Susceptibility or Resistance to NMO and\nMultiple Sclerosis among the French Afro-Caribbean Population. Mult. Scler.\n2011;17:24\u201331. doi: 10.1177/1352458510382810. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n70\\. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi\nG., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of\nMultiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol.\n2018;17:162\u2013173. doi: 10.1016/S1474-4422(17)30470-2. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n71\\. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart\nS., Perez J.L., P\u00e9rez Marc G., Moreira E.D., Zerbini C., et al. Safety and\nEfficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med.\n2020;383:2603\u20132615. doi: 10.1056/NEJMoa2034577. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n72\\. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R.,\nDiemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety\nof the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403\u2013416. doi:\n10.1056/NEJMoa2035389. [PMC free article] [PubMed] [CrossRef] [Google Scholar]\n[Ref list]\n\n73\\. Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-\nRammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al.\nSafety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine against SARS-CoV-2: A\nPreliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial.\nLancet. 2020;396:467\u2013478. doi: 10.1016/S0140-6736(20)31604-4. [PMC free\narticle] [PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n74\\. Sadoff J., Gray G., Vandebosch A., C\u00e1rdenas V., Shukarev G., Grinsztejn\nB., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and\nEfficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med.\n2021;384:2187\u20132201. doi: 10.1056/NEJMoa2101544. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n75\\. Herman C., Mayer K., Sarwal A. Scoping Review of Prevalence of Neurologic\nComorbidities in Patients Hospitalized for COVID-19. Neurology. 2020;95:77\u201384.\ndoi: 10.1212/WNL.0000000000009673. [PubMed] [CrossRef] [Google Scholar] [Ref\nlist]\n\n76\\. [(accessed on 10 March 2024)]. Available online:\nhttps://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-\nupdate/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-\nastrazeneca-14-april-2021_en.pdf [Ref list]\n\n77\\. Spagni G., Todi L., Monte G., Valentini M., Di Sante G., Damato V.,\nMarino M., Evoli A., Lantieri F., Provenzano C. Human Leukocyte Antigen Class\nII Associations in Late-Onset Myasthenia Gravis. Ann. Clin. Transl. Neurol.\n2021;8:656\u2013665. doi: 10.1002/acn3.51309. [PMC free article] [PubMed]\n[CrossRef] [Google Scholar] [Ref list]\n\n78\\. Di Sante G., Tolusso B., Fedele A.L., Gremese E., Alivernini S., Nicol\u00f2\nC., Ria F., Ferraccioli G. Collagen Specific T-Cell Repertoire and HLA-DR\nAlleles: Biomarkers of Active Refractory Rheumatoid Arthritis. eBioMedicine.\n2015;2:2037\u20132045. doi: 10.1016/j.ebiom.2015.11.019. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n79\\. Marino M., Maiuri M.T., Di Sante G., Scuderi F., La Carpia F., Trakas N.,\nProvenzano C., Zisimopoulou P., Ria F., Tzartos S.J., et al. T Cell Repertoire\nin DQ5-Positive MuSK-Positive Myasthenia Gravis Patients. J. Autoimmun.\n2014;52:113\u2013121. doi: 10.1016/j.jaut.2013.12.007. [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n80\\. Di Sante G., Gremese E., Tolusso B., Cattani P., Di Mario C., Marchetti\nS., Alivernini S., Tredicine M., Petricca L., Palucci I., et al. Haemophilus\nParasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry\nand Inflammation in Rheumatoid Arthritis. Front. Med. 2021;8:671018. doi:\n10.3389/fmed.2021.671018. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n81\\. Confavreux C., Suissa S., Saddier P., Bourd\u00e8s V., Vukusic S., Vaccines in\nMultiple Sclerosis Study Group Vaccinations and the Risk of Relapse in\nMultiple Sclerosis Vaccines in Multiple Sclerosis Study Group. N. Engl. J.\nMed. 2001;344:319\u2013326. doi: 10.1056/NEJM200102013440501. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n82\\. Olsson T., Barcellos L.F., Alfredsson L. Interactions between Genetic,\nLifestyle and Environmental Risk Factors for Multiple Sclerosis. Nat. Rev.\nNeurol. 2017;13:25\u201336. doi: 10.1038/nrneurol.2016.187. [PubMed] [CrossRef]\n[Google Scholar] [Ref list]\n\n83\\. Alfredsson L., Olsson T. Lifestyle and Environmental Factors in Multiple\nSclerosis. Cold Spring Harb. Perspect. Med. 2019;9:a028944. doi:\n10.1101/cshperspect.a028944. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n84\\. Goodin D.S., Khankhanian P., Gourraud P.-A., Vince N. The Nature of\nGenetic and Environmental Susceptibility to Multiple Sclerosis. PLoS ONE.\n2021;16:e0246157. doi: 10.1371/journal.pone.0246157. [PMC free article]\n[PubMed] [CrossRef] [Google Scholar] [Ref list]\n\n85\\. Pandolfi F., Cianci R., Casciano F., Pagliari D., De Pasquale T.,\nLandolfi R., Di Sante G., Kurnick J.T., Ria F. Skewed T-Cell Receptor\nRepertoire: More than a Marker of Malignancy, a Tool to Dissect the\nImmunopathology of Inflammatory Diseases. J. Biol. Regul. Homeost. Agents.\n2011;25:153\u2013161. [PubMed] [Google Scholar] [Ref list]\n\n86\\. Nicol\u00f2 C., Di Sante G., Procoli A., Migliara G., Piermattei A., Valentini\nM., Delogu G., Cittadini A., Constantin G., Ria F. M tuberculosis in the\nAdjuvant Modulates Time of Appearance of CNS-Specific Effector T Cells in the\nSpleen through a Polymorphic Site of TLR2. PLoS ONE. 2013;8:e55819. doi:\n10.1371/journal.pone.0055819. [PMC free article] [PubMed] [CrossRef] [Google\nScholar] [Ref list]\n\n###### Other Formats\n\n  * PDF (1.3M)\n\n###### Actions\n\n  * Add to Collections\n\n###### Share\n\n  * Permalink\n\n###### RESOURCES\n\nCite\n\nDownload .nbib .nbib\n\nFollow NCBI\n\nConnect with NLM\n\nNational Library of Medicine 8600 Rockville Pike Bethesda, MD 20894\n\nWeb Policies FOIA HHS Vulnerability Disclosure\n\nHelp Accessibility Careers\n\nExternal link. Please review our privacy policy.\n\n", "frontpage": false}
